Black Titan (NASDAQ:BTTC) Posts Quarterly Earnings Results

Black Titan (NASDAQ:BTTC) issued its quarterly earnings data on Tuesday. The company reported ($1.81) earnings per share for the quarter, FiscalAI reports.

Black Titan Trading Down 1.2%

NASDAQ BTTC traded down $0.02 during trading hours on Thursday, hitting $1.59. The company had a trading volume of 55,741 shares, compared to its average volume of 2,394,407. Black Titan has a fifty-two week low of $1.51 and a fifty-two week high of $39.00. The company has a market cap of $14.45 million, a P/E ratio of -0.54 and a beta of 1.38.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. Armistice Capital LLC bought a new stake in shares of Black Titan in the fourth quarter worth $840,000. Marex Group plc acquired a new stake in shares of Black Titan in the fourth quarter valued at approximately $84,000. HRT Financial LP acquired a new position in Black Titan during the 4th quarter valued at about $28,000. Finally, Renaissance Technologies LLC bought a new position in Black Titan during the fourth quarter valued at about $26,000.

Wall Street Analyst Weigh In

Separately, Weiss Ratings began coverage on Black Titan in a research note on Monday, January 26th. They set a “sell (e-)” rating on the stock. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Black Titan has a consensus rating of “Sell”.

Black Titan Company Profile

Titan Pharmaceuticals, Inc is a biopharmaceutical company developingproprietary therapeutics for the treatment of central nervous system disorders, cancer, and other serious and life threatening diseases. In the central nervous system arena, the company is developing iloperidone, which is clinical testing for schizophrenia through a licensing and development agreement with Novartis Pharma AG. Novartis has tradenamed the product Zomaril.